- NuVasive (NUVA +0.6%) announces the limited availability of the new Precice Plate for use in limb lengthening and reconstruction procedures from NuVasive Specialized Orthopedics (NSO).
- The Precice Plate extends the clinical benefits to pediatrics or patients with small anatomy that cannot accommodate a lengthening device, traditionally implanted within the patient's bone.
- "With a less invasive treatment protocol and at-home precision lengthening, the availability of the Precice Plate directly reflects NuVasive's commitment to grow its proprietary technology," said Rob Martin, general manager of NSO.
- NSO plans full commercial launch of the Precice Plate in the US and Europe in early 2021.
- While Quant Rating is Neutral, SA Authors and Wall Street sell-siders are Bullish on NUVA with price target of $65.88.
- The market is pricing NuVasive for sub-20% EBITDA margins and low single-digit revenue growth; doing even modestly better should be enough to drive attractive returns, writes Author Stephen Simpson in his article "NuVasive's Valuation Prices In An Excessively Bearish Outlook" at Seeking Alpha.
